Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerFotios Loupakis, Alfredo Falcone, Silvana Chiara et al.|New England Journal of Medicine|2014Cited by 1.1k
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Vincenzo Guarini et al.|British Journal of Cancer|2020Cited by 350
Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary reportMartina Pecoraro, Valeria Panebianco, Francesco Del Giudice et al.|Abdominal Radiology|2021Cited by 75
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center TrialChiara Nicolazzo, Cristina Raimondi, Gian Maria Busetto et al.|The Oncologist|2019Cited by 54